Skip to main content
Signal8
Launch Terminal

BioAge Labs, Inc. (BIOA)

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BioAge Labs Inc. logo

BioAge Labs Inc.

NASDAQ:BIOAHealthcare
-1.18%$5.87
AH$5.87+0.00%vs close
Mkt Cap$269.41M
Float40.8M
O/S45.9M
Vol
$ Vol
RVOL
Inst Own82.9%
SI8.4%
Earnings
Dilution
BioAge Labs Inc. logoNASDAQ:BIOA$5.87-1.18%
Phase Distribution
7 lead-sponsored trials·2 active·1 completed
Phase 11
Phase 26
Status Overview
Recruiting1
Active, not recruiting1
Completed1
Stopped4

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Terminated

    Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

    BGE-175

    Covid19

    Enrollment
    194
    Start
    Mar 2021
    Primary Completion
    Apr 2022
    Completion
    May 2022
    NCT04705597
  • Phase 2
    Withdrawn

    Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging

    BGE-117

    Anemia

    Enrollment
    0
    Start
    Mar 2021
    Primary Completion
    Apr 2022est.
    Completion
    Apr 2022est.
    NCT04815603
  • Phase 2
    Withdrawn

    Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery

    BGE-117, 4mg, BGE-117, 12mg

    Acute Posthemorrhagic Anemia

    Enrollment
    0
    Start
    Apr 2022est.
    Primary Completion
    Apr 2023est.
    Completion
    Jul 2024est.
    NCT05152641
  • Phase 2
    Terminated

    Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

    Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105)

    Obesity

    Enrollment
    204
    Start
    Jun 2024
    Primary Completion
    Feb 2025
    Completion
    Feb 2025
    NCT06515418
  • Phase 2
    Active, not recruiting

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Oral BGE-102, Oral Placebo Matching BGE-102

    Obesity and Cardiovascular Risk

    Enrollment
    160
    Start
    Jun 2026
    Primary Completion
    Nov 2026est.
    Completion
    Dec 2026est.
    NCT07656727
  • Phase 2
    Recruiting

    A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

    Oral BGE-102, Oral Placebo Matching BGE-102

    Diabetic Macular Edema (DME)

    Enrollment
    180
    Start
    Aug 2026
    Primary Completion
    Nov 2027est.
    Completion
    Dec 2027est.
    NCT07812090
  • Phase 1
    Completed

    Pharmacokinetics Study of Azelaprag (BGE-105) in Older Adult Healthy Volunteers

    Azelaprag

    Healthy Volunteer Study

    Enrollment
    16
    Start
    Nov 2023
    Primary Completion
    Jan 2024
    Completion
    Feb 2024
    NCT06141889
Search ClinicalTrials.gov for “BioAge Labs”